IDENTIFICATION OF DRUG-RELATED PROBLEMS IN ADULTS WITH TUBERCULOSIS AT THE TEBET SUBDISTRICT HEALTH CENTER FROM JULY TO DECEMBER 2018
DOI:
https://doi.org/10.22159/ijap.2020.v12s1.FF010Keywords:
Tuberculosis, Mycobacterium tuberculosis, Antituberculosis, Drug-related problems, CipolleAbstract
Objective: Tuberculosis (TB) is a highly prevalent infectious disease caused by Mycobacterium tuberculosis. The recommended TB treatment is a
combination of various antibiotics in the form of a fixed-dose combination tablet or kombipak; however, this increases the prevalence of drug-related
problems. Therefore, this study aimed to identify drug-related problems of patients receiving TB therapy at the Tebet Subdistrict Health Center from
July 2018 to December 2018.
Methods: The study was designed as a cross-sectional study using the retrospective data retrieval method from prescriptions of patients with
TB from July 2018 to December 2018. The classification system prepared by Cipolle, Strand, and Morley was used for the classification of drugrelated
problems; this system includes unnecessary drug therapy, required additional drug therapy, ineffective drug, dosage error, and drug
interaction.
Results: The percentage of unnecessary drug therapy, required additional drug therapy, ineffective drug, dosage error, and drug interaction was
2.85%, 6.89%, 1.54%, 12.46%, and 66.18%, respectively, with the occurrence of drug-related problems being the highest.
Conclusion: The administration of anti-TB drugs can potentially cause drug-related problems. Therefore, the assessment needs to be optimized
before the administration of medications to patients and medications should be prescribed and monitored regularly to achieve rational drug use
Downloads
References
Handbook. 9th ed. Inggris: McGraw-Hill Education Companies; 2015.
2. World Health Organization. Tuberculosis; 2018. Available from: https://
www.who.int/news-room/fact-sheets/detail/tuberculosis.
3. Ministry of Health, Republic of Indonesia. Data and Information Center
of the Indonesian Ministry of Health, Tuberculosis. Jakarta: Ministry of
Health, Republic of Indonesia; 2018.
4. Nugrahaeni DK, Hadisaputro S, Suwondo A, Dharmana E. The effect
of alpha-mangostin in balancing the ratio of cytokines pro-and antiinflammation-
gamma (ifn- ?/il-10) and severity of the disease in mice
infected with Mycobacterium tuberculosis multidrug-resistant. Asian J
Pharm Clin Res 2016;9:273-7.
5. Pitaloka DA, Sukandar EY. In vitro study of ursolic acid combination
first-line antituberculosis drugs against drug-sensitive and drugresistant
strains of Mycobacterium tuberculosis. Asian J Pharm Clin
Res 2017;10:216-8.
6. Ismail A, Handayany GN, Bakri M. Evaluation of the use of antituberculosis
drugs anti-TB drug in pulmonary tuberculosis patients at
the Jumpandang Baru Health Center, Makassar. J Farm Fak Kedokteran
Ilmu Kesehatan UIN Alauddin 2017;4:194-206.
7. Ministry of Health, Republic of Indonesia. This is the Rational Use
of Drugs that must be Understood by the Public. Communication and
Community Service Bureau. Jakarta: Ministry of Health, Republic of
Indonesia; 2018. Available from: http://www.sehatnegeriku.kemkes.
go.id/baca/umum/20180329/3525429/inilah-penggunaan-obatrasional-
yang-harus-dipahami-masyarakat.
8. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis
drugs: Drug interactions, adverse effects, and use in special situations.
Part 1: First-line drugs. J Bras Pneumol 2010;36:626-40.
9. Muniroh N, Aisah S. Factors related to recovery of pulmonary
tuberculosis (TB) in the working area of Mangkang Public Health
Center, West Semarang. J Keperawatan Komunitas 2013;1:33-4.
10. Nugraheni K, Malik U. Analysis of the causes of anti-tuberculosis
drug resistance [Analisis penyebab resistensi obat anti tuberculosis].
J Kesehatan Masyarakat 2015;11:8-15.
11. Kumar YA, Kumar VR, Ahmad A, Mohanta GP, Manna PK. Pharmacist
interventions and pharmaceutical care in an Indian teaching-hospital:
A prospective study. Int J Adv Res Biol Sci 2012;1:386-96.
12. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice:
The Patient-centered Approach to Medication Management. 3rd ed.
New York: McGraw-Hill Education Companies; 2012.
13. Shivaraj G, Muralikhrisna K, Nijeesh CH, Laloo F, Baburaja B,
Doddayya H. Study on drug-related problems in tuberculosis patients
with comorbidities in a tertiary care teaching hospital. Eur J Pharm Med
Res 2017;4:756-67.
14. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice.
New York: McGraw-Hill; 1998. p. 78-9.
15. Dotulong JF, Sapulete MR, Kandou GD. Relationship between risk factors
for age, sex, and occupancy density with the incidence of pulmonary TB
disease at Wori regency. J Kedokt Komunitas Tropik 2015;3:57-65.
16. Chinnakali P, Selvaraj K, Thekkur P, Ramasamy G, Thulasingam M,
Vasudevan K. Age and sex differences in sputum smear microscopy
results for acid fast bacilli in a tertiary care centre, South India. J Respir
Med 2014;2014:1-5.
17. van den Hof S, Najlis CA, Bloss E, Straetemans M. A Systematic
Review on the Role of Gender in Tuberculosis Control. United States,
Washington, DC: Agency for International Development; 2010.
18. Kurnianingsih L, Sudirman I, Utaminingrum W. Identification of
Drug Related Problems Treating Tuberculosis in Outpatients at
RSUD Kardinah, Tegal in 2009, Thesis. Tegal: Faculty of Pharmacy
Universitas Muhammadiyah Purwokerto; 2010.
19. Ministry of Health, Republic of Indonesia. National Guidelines
for Tuberculosis Control. Jakarta: Ministry of Health, Republic of
Indonesia; 2014.
20. Ningrum VD, Megasari A, Hanifah S. Hepatotoksisitas pada pengobatan
tuberkulosis di RSUD Tangerang Indonesia. J Ilmiah Farm 2010;7:49-7.
Published
How to Cite
Issue
Section
